Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases, including psoriasis. OBJECTIVE: The primary objective was to evaluate the safety of repeat doses of dalazatide in adult patients with mild-to-moderate plaque psoriasis. Secondary objectives were to evaluate clinical proof of concept and the effects of dalazatide on mediators of inflammation in the blood and on chronically activated memory T cell populations. METHODS: Patients (n = 24) were randomized 5:5:2 to receive dalazatide at 30 mcg/dose, 60 mcg/dose, or placebo twice weekly by subcutaneous injection (9 doses total). Safety was assessed on the basis of physical and neurological examination and laboratory testing. Clinical assessments included body-surface area affected, Psoriasis Area and Severity Index (PASI), and investigator and patient questionnaires. RESULTS: The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. Nine of 10 patients in the 60 mcg/dose group had a reduction in their PASI score between baseline and Day 32, and the mean reduction in PASI score was significant in this group (P < 0.01). Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells. LIMITATIONS: The study was small and drug treatment was for a short duration (4 weeks). CONCLUSION: This study indicates that dalazatide is generally well tolerated and can improve psoriatic skin lesions by modulating T cell surface and activation marker expression and inhibiting mediators of inflammation in the blood. Larger studies of longer duration are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the only class of Kv1.3 channel blockers that has successfully completed phase Ib studies in humans for psoriasis (ShK analogs) has not been tested in pre-clinical models of AD pathology [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ShK-223 was selected due to its improved stability and > 10,000-fold selectivity for Kv1.3 channels over neuronal Kv channels [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“Our pre-clinical findings using ShK-223 are of translational importance because a Kv1.3-blocking ShK analog (dalazatide or ShK-186) that is very similar to ShK-223, is the only selective Kv1.3 blocker to have successfully completed early phase human studies for systemic autoimmunity [53].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweiger, D., Baufeld, C., Drescher, P., Oltrogge, B., Höpfner, S., Mess, A., Lüttke, J., Rippke, F., Filbry, A., & Max, H. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000348473 · Cited by 1,346
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Resident memory T cells in human health and disease
Clark, R. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010641 · Cited by 446
The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422
Cited by
Items 101–168 of 168
A Comparative Analysis of the Venom System between Two Morphotypes of the Sea Anemone Actinia equina
Alcaide, M., Cabral, I. M., Carvalho, L. A. D. P., Mendes, V. M., Matos, A., Manadas, B. J., Saúde, L., D’Ambrosio, M., & Costa, P. M. (2024) · Animals · doi:10.3390/ani14060981 · Cited by 8
“3 potassium channel and has been subjected to trials for the treatment and management of autoimmune diseases such as psoriasis [10], rheumatoid arthritis [11], obesity and insulin resistance [12].”
BackgroundShK toxin: history, structure and therapeutic applications for autoimmune diseases
Chang, S. C., Bajaj, S., & Chandy, K. G. (2018) · WikiJournal of Science · doi:10.15347/wjs/2018.003 · Cited by 8
“These patients also exhibited reduced plasma levels of multiple inflammation markers and decreased expression of T cell activation markers on peripheral blood memory T cells.([7])”
BackgroundInfluentialHarnessing Deep Learning Methods for Voltage-Gated Ion Channel Drug Discovery
Mateos, D. L., Harris, B. J., González, A. H., Narang, K., & Yarov-Yarovoy, V. M. (2024) · Physiology · doi:10.1152/physiol.00029.2024 · Cited by 9
Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel
Vasseur, L., Chavanieu, A., Combemale, S., Caumes, C., Béroud, R., WAARD, M. M. D., Ducrot, P., Boutin, J. A., Ferry, G., & Cens, T. (2019) · Toxicon X · doi:10.1016/j.toxcx.2019.100010 · Cited by 7
“3 voltage-gated K channel inhibitor used in clinical trials to treat plaque psoriasis (Tarcha et al., 2017).”
MethodShioi, N., Nomura, S., Tanaka, Y., & Hirose, S. (2025) · Toxins · doi:10.3390/toxins17120579 · Cited by 9
“In a Phase 1b clinical trial in patients with plaque psoriasis, Dalazatide was generally well tolerated and reduced both skin lesion severity and inflammatory biomarkers [150].”
Krämer, J., Hoelker, P., & Predel, R. (2024) · Toxins · doi:10.3390/toxins16060272 · Cited by 7
Manville, R. W., Yoshimura, R. F., Yeromin, A. V., Hogenkamp, D. J., van der Horst, J., Zavala, A., Chinedu, S., Arena, G., Lasky, E., Fisher, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06752-y · Cited by 6
“3 blocker ameliorated symptoms in animal models of multiple sclerosis 25,26 , and in treatment of plaque psoriasis in a limited PhaseIbhumanclinicaltrial 27 .”
Synthesis and Hypoglycemic Effect of Insulin from the Venom of Sea Anemone Exaiptasia diaphana
Guo, Q., Tang, T., Lu, J., Huang, M., Zhang, J., Ma, L., & Gao, B. (2024) · Marine Drugs · doi:10.3390/md22030111 · Cited by 6
“…as ShK-186), derived from sea anemone Stichodactyla helianthus , was found to selectively block K V 1.3 channel, and it represents a significant area of study for its therapeutic potential in autoimmune and inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis [6,7].”
BackgroundInfluentialExpression and function of Kv1.3 channel in malignant T cells in Sézary syndrome
Hu, T., Buus, T. B., Krejsgaard, T., Nansen, A., Lundholt, B. K., Spee, P., Fredholm, S., Petersen, D. L., Blümel, E. P., Gluud, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27122 · Cited by 6
“3 inhibitors have shown efficacy in preclinical animal models [48–50], and one inhibitor, Dalazatide, is now in clinical trials for psoriasis [51], suggesting that Kv1.”
BackgroundMethotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region
Xie, Z., Zhao, Y., Yang, W., Li, W., Wu, Y., & Chen, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.050 · Cited by 5
Sanches, K., Ashwood, L. M., Olushola‐Siedoks, A. A., Wai, D. C. C., Rahman, A., Shakeel, K., Naseem, M. U., Panyi, G., Prentis, P. J., & Norton, R. S. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26594 · Cited by 6
“17 Since its discovery in a sea anemone, the ShKT domain has been found in numerous other species, including plants, algae, protozoa, other cnidarians (such as hydra and jellyfish), sea urchins, mollusks, sea squirts, fish, nematodes, parasitic worms, snakes, amphibians, birds, and mammals.”
BackgroundIon Channels as Targets in Drug Discovery: Outlook and Perspectives
Stevens, E. B., & Stephens, G. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_1 · Cited by 8
Metabolic and ionic control of T cells in asthma endotypes
Franz, T. J., Stegemann‐Koniszewski, S., Schreiber, J., Müller, A. J., Bruder, D., Dudeck, A., Boehme, J. D., & Kahlfuß, S. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2024 · Cited by 6
Hua, Z., Liao, Y., Fu, J., Li, X., Xu, Q., Lin, L., Huang, M., & Gao, B. (2024) · Marine Drugs · doi:10.3390/md22100470 · Cited by 5
Rathnam, S. S., Deepak, T., Sahoo, B. N., Meena, T., Singh, Y., & Joshi, A. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001689 · Cited by 7
Zhang, G., Jia, H., Luo, L., Zhang, Y., Cen, X., Yao, G., Zhang, H., He, M., & Liu, W. (2022) · Marine Drugs · doi:10.3390/md20110686 · Cited by 4
Structure and functional studies of Avt1, a novel peptide from the sea anemone Aulactinia veratra
Albar, R. A. A., Smith, H. L., Sanches, K., Wai, D. C. C., Naseem, M. U., Szanto, T. G., Panyi, G., Prentis, P. J., & Norton, R. S. (2024) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2024.141050 · Cited by 4
Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Al-Suhaimi, E. A., Ravinayagam, V., Jermy, B. R., Tarhini, M., & Elaïssari, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152320 · Cited by 4
Hu, T., Krejsgaard, T., Nastasi, C., Buus, T. B., Nansen, A., Hald, A., Spee, P., Nielsen, P. R., Blümel, E. P., Gluud, M., et al. (2019) · Dermatology · doi:10.1159/000502137 · Cited by 5
Zeldin, J., Jordan, J., Thota, P., Vuong, R., Jojo, C., & Myles, I. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1585525 · Cited by 3
Advances in treatment of psoriatic arthritis: current guidelines and emerging therapies
Feldkamp, A. M., & Raychaudhuri, S. P. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102658 · Cited by 3
Cnidarian toxins: omics approaches and recombinant proteins
Vega-Tamayo, J. E., Alcantar-Orozco, E. D. J., Mendoza-Ramírez, R. A., Silva-Díaz, L. G., Aguilar-Salazar, J. A., Salvador-Aguilar, D. H., & Rojas‐Molina, A. (2025) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1590/1678-9199-jvatitd-2025-0019 · Cited by 4
“Based on these findings, ShK-186 progressed to phase 1 clinical trials, where it was evaluated in patients with mild to moderate plaque psoriasis [216].”
Kim, Y., Jo, Y., Lee, S. E., Kim, J., Choi, J.-P., Lee, N., Won, H., Woo, D. H., & Yum, S. (2024) · Marine Drugs · doi:10.3390/md22050217 · Cited by 5
“3 has become a therapeutic target for the treatment Among the e ff ective potassium channel blockers, an ShK-186 analog was the fi rst candidate drug to display clinically useful traits [17,18]. of these diseases [14–16].”
BackgroundXiao, Z., You, X., Chen, M., Li, H., Chen, B., Hu, Z., You, Q., Liu, H., Zhao, P., Zhou, X. J., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108341 · Cited by 7
“Dalazatide has successfully completed phase 1b clinical trials in mild-to-moderate plaque psoriasis (14).”
Liu, Y., Zhang, J., Wang, R., Wu, Y., Wang, W., Xin, X., Du, M., Cao, Y., & Zhang, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.014 · Cited by 3
Orlov, N. A., Yakimov, S. A., Nekrasova, O. V., & Feofanov, A. V. (2022) · Moscow University Biological Sciences Bulletin · doi:10.3103/s0096392522020067 · Cited by 3
Szekér, P., Bodó, T., Klima, K., Csóti, A., Hanh, N. N., Murányi, J., Hajdara, A., Szanto, T. G., Panyi, G., Megyeri, M., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107155 · Cited by 2
“2 ion channels by Dalazatide and/or its metabolite that readily forms upon exposure to human plasma (15).”
BackgroundZakariya, M., Lincoln, O. J., D’Ambra, I., & Lauritano, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136109 · Cited by 2
“3 blockade and may offer a possible treatment strategy for patients with granulomatosis with polyangiitis (GPA) with high specificity and fewer side effects; Dalazatide is also reported in a Phase 1b trial for the treatment of plaque psoriasis [47,48].”
Wang, Y., Wang, Q., Li, R., Yu, Y., Feng, S., Wu, W., & Ren, S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107185 · Cited by 2
Kour, D., Srivastava, U., Eddy, T., Mehta, L., Kumari, R., & Rangaraju, S. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102757 · Cited by 2
Okada, T., Taira, H., & Kimura, T. (2022) · Venoms and Toxins · doi:10.2174/2666121702666220429095250 · Cited by 2
New aspects of the pathogenesis of psoriasis
Zhukov, A. S., Патрушев, А. В., Khairutdinov, V. R., Samtsov, A. V., & Kryukov, E. V. (2022) · Vestnik dermatologii i venerologii · doi:10.25208/vdv1345 · Cited by 2
“Studies of the 1st phase of the drug which inhibit resident memory T cells in psoriasis patients have already been completed and the first positive results have been obtained [65].”
BackgroundImmune Cell Ion Channels as Therapeutic Targets
Selezneva, A. I., Gibb, A. J., & Willis, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_14 · Cited by 4
Role of ion channels in immune regulation of psoriasis
Uchida, H., Wu, X., Zhou, Y., Zheng, J., Wulff, H., & Hwang, S. T. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102688 · Cited by 4
Ion Channels as Therapeutic Drug Targets
García, M. L., & Kaczorowski, G. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc255 · Cited by 2
Kuznetsova, K. G., Zvonareva, S. S., Ziganshin, R., Mekhova, E. S., Dgebuadze, P. Y., Yen, D. T. H., Nguyen, T., Moshkovskii, S. A., & Fedosov, A. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.15.476460 · Cited by 2
Professor Alan Lang Harvey (1950–2020)
Warrell, D. A., & Rowan, E. G. (2022) · Toxicon · doi:10.1016/j.toxicon.2022.03.001 · Cited by 1
Dong, Y. Y., Wang, J., Zhu, Y., Zhao, L., Zeng, Y., Tang, L., Xiao, Q., Cheng, J., Wang, C., & Tao, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754290 · Cited by 1
Navarro‐Pérez, M., Pérez-Verdaguer, M., Benavente-Garcia, A., Dustin, M. L., Felipe, A., & Capera, J. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06202-4 · Cited by 1
Clinical and preclinical data on therapeutic peptides
Mahari, S., Shahdeo, D., Banga, I. K., Choudhury, S., & Gandhi, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00007-8 · Cited by 1
Wang, Y., Hurley, A. E., Giorgi, M. D., Tanner, M. R., Hu, R.-C., Pennington, M. W., Lagor, W. R., & Beeton, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283996 · Cited by 2
Can venoms be used in neuroprotection?
Gazerani, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00003-8 · Cited by 1
Ion Channel Tools and Therapeutics from Venoms and Toxins
Trim, C. M., Leffler, A. E., Samanani, Z., & Trim, S. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_15 · Cited by 1
Carden, H., Dallas, M. L., Hughes, D. J., Lippiat, J. D., Mankouri, J., & Whitehouse, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.10.459757 · Cited by 1
Ashwood, L. M., Elnahriry, K. A., Stewart, Z. K., Shafee, T. M. A., Naseem, M. U., Szanto, T. G., van der Burg, C. A., Smith, H. L., Surm, J. M., Undheim, E. A. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.08.518931 · Cited by 1
“An analogue of ShK (dalazatide, Shk-186) has shown remarkable efficacy in in preclinical animal models of autoimmune disease [15, 19-21] and entered phase 1 clinical trials for the treatment of plaque psoriasis [22].”
Kim, Y., Jo, Y., Lee, S. E., Kim, J., Choi, J., Lee, N., Won, H., Woo, D. H., & Yum, S. (2023) · Preprints.org · doi:10.20944/preprints202309.1253.v1 · Cited by 1
Characterising the functional venom profiles of sea anemones
Ashwood, L. M. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.227457
Leal, E., Bolívar, L. P. S., & Múnera, M. (2022) · Revista de Biología Tropical · doi:10.15517/rev.biol.trop..v70i1.49798 · Cited by 2
Characterization of endogenous Kv1.3 channel isoforms in T cells.
Pérez, J. S. (2023) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/63662
Dysfunctional K+ Homeostasis as a Driver for Brain Inflammation
Ozsoy, N., & Dallas, M. L. (2024) · Encyclopedia · doi:10.3390/encyclopedia4040110 · Cited by 1
“Dalazatide’s success in managing autoimmune diseases like psoriasis has highlighted its potential broader application in CNS disorders where inflammation is a critical factor [56].”
Monteiro, I. D. S., de Araújo, I. F. S., Camargos, T. S., Ortíz, E., de Souza, A. C. B., de Lima, J. D., Possani, L. D., Schwartz, E. F., & Tibery, D. V. (2025) · Toxins · doi:10.3390/toxins17020096
“3 blocker that has undergone phase 1 clinical trials for the treatment of plaque psoriasis [81].”
A comparative analysis of toxin gene families across diverse sea anemone species
Smith, H. L., Broszczak, D. A., van der Burg, C. A., Surm, J. M., Liggins, L., Norton, R. S., & Prentis, P. J. (2025) · Toxicon X · doi:10.1016/j.toxcx.2025.100217
“…such as ShK, APETx4, ATX-I, ATX-II and ShI (Beeton et al., 2011; Chi et al., 2012; Honma and Shiomi, 2006; Kem et al., 1989; Moreels et al., 2017; Norton, 2009; Pennington et al., 2009; Prentis et al., 2018; Schweitz et al., 1981; Sintsova et al., 2023; Tarcha et al., 2017; Upadhyay et al., 2013).”
Licochalcone D Alleviates Psoriasiform Skin Inflammation by Inhibiting Kv1.3 Channels
Long, H., Xiang, Q., Lan, Z., Bai, L., & Yin, S. (2025) · Science Discovery · doi:10.11648/j.sd.20251306.17
Zhao, Y., Zuo, Z., Qin, C., Chen, Z., Cao, Z., & Wu, Y. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150379
Pereira, G. H. F., Cruz, D., Júnior, R. S., Pinto, L. S., Stampar, S. N., & Toledo, K. A. (2025) · Brazilian Journal of Biology · doi:10.1590/1519-6984.297214
Toxicity induced by ion channel targeting drugs: Mechanisms and mitigation strategies
Krüger, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00070-4
Synthèse de peptides bioactifs inspirés des venins
Giribaldi, J. (2019) · theses.fr (ABES) · doi:10.70675/4396528bz40f7z47abz935az5799907cf557
Mise au point et industrialisation de la synthèse de peptides complexes
Zoukimian, C. (2020) · theses.fr (ABES) · doi:10.70675/70599ebdzae74z4c3cza458zd687d73592cc
Des toxines animales comme ligands innovants des récepteurs aux mélanocortines
Reynaud, S. (2019) · theses.fr (ABES) · doi:10.70675/3b7e4bedz99ffz4cbaz82c0za19291184a87
Where are peptide ligands of potassium channels sourced from?
Kuzmenkov, A. I., & Vassilevski, A. A. (2026) · Molecular Pharmacology · doi:10.1016/j.molpha.2026.100135
Zhang, D., Cao, S., He, S., Mao, S., Luo, S., & Ding, L. (2026) · Medicinal Research Reviews · doi:10.1002/med.70067
“…and websites, we have compiled a summary of compounds targeting ion channels involved in clinical trials from 2000 to 2025, aiming to gain a better understanding of the current clinical landscape (Table 1) (https://go.drugbank.com/ ; https://www.nlm.nih.gov/; https://data.pharmacodia.com/) [26–39].”
Kim, G., Wang, Z., Li, Y., Liu, Y., Lian, H., Chen, R., Huang, H., Lin, J., & Ni, X. (2026) · Translational research · doi:10.1016/j.trsl.2026.06.020
Scorpion Venom and Biodegradable Biomaterials
Housseini, A. E., Rachmoune, K., aimani, S. E., Joud, Y. E., Hidan, M. A. E., Laghzaoui, E.-M., Laaradia, M. A., Mouden, E. H. E., & Agnaou, M. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-0060-1.ch010
Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution
Lin, L., Mitchell, T. R., Sanches, K., Abdallah, M., Ren, Y., Farooq, M. A., Song, H., Qu, J., Chen, Z., Nardo, W. D., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127198
Chen, J., Chen, Z., Sun, S., Lyu, C., Li, M., Song, Y., & Gao, B. (2026) · Marine Drugs · doi:10.3390/md24080276
“For instance, Dalazatide, derived from well-known ShK peptide, has been verified in the inhibition of K v 1.3 channels in human T lymphocytes, making it an excellent candidate for clinical therapeutics of autoimmune diseases [6].”
InfluentialCnidarian Venoms in the Omics Era: Toxin Discovery and Bioactive Potential
Barroso, R. A., & Antunes, A. (2026) · Marine Drugs · doi:10.3390/md24090306 · Cited by 1
Zhen, W.-J., Ye, J.-Q., Xia, G., Chen, X.-X., Tian, Y.-Y., Chen, S., Wang, M.-Q., Jia, L.-X., Zhang, Q., Wang, Y.-T., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119310
BindingDB Entry 50002554: Peptide therapeutics from venom: Current status and potential.
BindingDB (2020) · UC San Diego · doi:10.7270/q2q52s8q
Metadata
- Authors
- Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P.
- Affiliations
- Kineta (United States) (US)
- Rockefeller University (US)
- Corresponding author
- Olsen, Chelsea M.
- ORCID
- Olsen, Chelsea M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-07-19
- Volume
- 12
- Issue
- 7
- Pages
- e0180762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5516987
- OpenAlex
- W2737389332
- Cited by
- 167
- References
- 48
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 25 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 20 · 2018: 13 · 2017: 6
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- plaque psoriasis, memory T cells, drug safety, pharmacodynamics, numbness, paresthesia, inflammatory markers, T cell activation markers, PASI, subcutaneous injection
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Hypesthesia, Male, Middle Aged, Paresthesia, Proteins, Psoriasis, Treatment Outcome, Potassium Channel Blockers, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.